The PKA-CREB1 axis regulates coronavirus proliferation by viral helicase nsp13 association
Journal of Virology · 2024
DOI: 10.1128/jvi.01565-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Tong Zheng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Genetic Engineering Research Laboratory, Beijing Institute of Biotechnology, Beijing, China. Hauptthemen laut MEDLINE: Coronavirus RNA-Dependent RNA Polymerase, Cyclic AMP Response Element-Binding Protein, Cyclic AMP-Dependent Protein Kinases, Host Microbial Interactions. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a worldwide threat in the past 3 years. Although it has been widely and intensively investigated, the mechanism underlying the coronavirus-host interaction requires further elucidation, which may contribute to the development of new antiviral strategies. Here, we demonstrated that the host cAMP-responsive element-binding protein (CREB1) interacts with the non-structural protein 13 (nsp13) of SARS-CoV-2, a conserved helicase for coronavirus replication, both in cells and in lung tissues subjected to SARS-CoV-2 infection. The ATPase and helicase activity of viral nsp13 were shown to be potentiated by CREB1 association, as well as by Protein kinase A (PKA)-mediated CREB1 activation. SARS-CoV-2 replication is significantly suppressed by PKA Cα, cAMP-activated protein kinase catalytic subunit alpha (PRKACA), and CREB1 knockdown or inhibition. Consistently, the CREB1 inhibitor 666-15 has shown significant antiviral effects against both the WIV04 strain and the Omicron strain of the SARS-CoV-2. Our findings indicate that the PKA-CREB1 signaling axis may serve as a novel therapeutic target against coronavirus infection. IMPORTANCE In this study, we provide solid evidence that host transcription factor cAMP-responsive element-binding protein (CREB1) interacts directly with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) helicase non-structural protein 13 (nsp13) and potentiate its ATPase and helicase activity. And by live SARS-CoV-2 virus infection, the inhibition of CREB1 dramatically impairs SARS-CoV-2 replication in vivo . Notably, the IC50 of CREB1 inhibitor 666-15 is comparable to that of remdesivir. These results may extend to all highly pathogenic coronaviruses due to the conserved nsp13 sequences in the virus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genetic Engineering Research Laboratory, Beijing Institute of Biotechnology, Beijing, China.
- Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
- Institute of Physical Science and Information Technology, Anhui University, Hefei, Anhui, China.
- Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
ORCID-Profile: Hainan Liu, Yuwei Gao, Xuan Liu, Cheng Cao
Zitieren
APA
Zheng, T., Shen, B., Bai, Y., Li, E., Zhang, X., Hu, Y., Gao, T., Dong, Q., Zhu, L., Jin, R., Shi, H., Liu, H., Gao, Y., Liu, X., & Cao, C. (2024). The PKA-CREB1 axis regulates coronavirus proliferation by viral helicase nsp13 association. Journal of Virology. https://doi.org/10.1128/jvi.01565-23
Vancouver
Zheng T, Shen B, Bai Y, Li E, Zhang X, Hu Y, et al. The PKA-CREB1 axis regulates coronavirus proliferation by viral helicase nsp13 association. Journal of Virology. 2024. doi:10.1128/jvi.01565-23
BibTeX
@article{Zheng2024,
author = {Zheng, Tong and Shen, Beilei and Bai, Yu and Li, Entao and Zhang, Xun and Hu, Yong and Gao, Ting and Dong, Qincai and Zhu, Lin and Jin, Rui and Shi, Hui and Liu, Hainan and Gao, Yuwei and Liu, Xuan and Cao, Cheng},
title = {The PKA-CREB1 axis regulates coronavirus proliferation by viral helicase nsp13 association},
journal = {Journal of Virology},
year = {2024},
doi = {10.1128/jvi.01565-23}
}
EUVIMED